



MOLECULAR GENETICS LABORATORY  
COMPREHENSIVE WHOLE EXOME SEQUENCING  
(WES)  
SERVICE REQUEST

FOR AJC  
Patient Code: \_\_\_\_\_  
USE ONLY  
Lab Order No.: \_\_\_\_\_

**Patient Information**

Name: \_\_\_\_\_ Gender:  Male  Female  
Date of Birth: / / CPR/ID No: \_\_\_\_\_ Nationality: \_\_\_\_\_ Clinically Affected:  Yes  No  
Parental Consanguinity:  Yes  No  
Relationship to Proband (if applicable):  Proband  Mother  Father  Sibling  Other: \_\_\_\_\_

**Referring Physician/Institution Details**

Referring Clinic/hospital: \_\_\_\_\_ Ordering Physician: \_\_\_\_\_ Dr. Signature & Stamp: \_\_\_\_\_  
Physician Phone: \_\_\_\_\_ Email: \_\_\_\_\_ Date: \_\_\_\_\_

**Type of Specimen**

EDTA Blood  DNA Patient has had blood transfusion:  Yes  No Date: \_\_\_\_\_  
Collection date: / / Patient has had bone marrow/organ transplant:  Yes  No Date: \_\_\_\_\_

**Test Requested**

DSMG015  Comprehensive Whole Exome Sequencing Solo (\*bsCNV + \*\*mtDNA)  
\*bsCNV: Backbone-supported Copy number variation (intronic/intergenic/large deletion/duplication)  
\*\*mtDNA: Mitochondrial DNA

Indication:  
 Diagnostic (symptomatic)  Secondary Findings (optional – ACMG SF v3.1)  Reanalysis  
\*ACMG: American College of Medical Genetics and Genomics – sets standards for genetic testing and variant interpretation.

**Clinical Information**

Clinical Diagnosis/Indication:  
\_\_\_\_\_

Clinical Summary/Symptoms:  
\_\_\_\_\_

Relevant Findings (imaging, metabolic, etc.):  
\_\_\_\_\_

Previous Genetic Testing (if any):  
\_\_\_\_\_

Onset Age:  
\_\_\_\_\_



**Phenotypic Information:** Please provide any additional information. Please avoid abbreviations and include any reference ranges for lab results.

**Further clinical information attached (if applicable):**

Previous Genetic Testing reports    Laboratory/Radiology Reports    Clinical Summary

**Family History:**

- Is there a family history of a similar condition?  Yes  No  Unknown
- Are there affected siblings?  Yes  No  No siblings
- Is the patient in/from a consanguineous marriage?  Yes  No  Unknown

**Pedigree:** Please provide any relevant family history in pedigree and/or written form



**Clinical Symptoms Information:**  Affected  Unaffected (Please tick the appropriate boxes)

BLOOD	CNS PHYSIOLOGY	HEAD AND FACE	MOVEMENT/MOTOR FUNCTION	SKELETAL 2/2
Abn. <sup>1</sup> of coagulation	Developmental regression	Craniosynostosis	Areflexia	Increased bone mineral density
Abn. <sup>1</sup> bleeding	Dysarthria	Depressed nasal bridge	Ataxia	Kyphosis
Anemia	Dysphagia	Dolichocephaly	Bradykinesia	Limb undergrowth
Hemolytic anemia	EEG abnormality	Epicanthus	Chorea	Pectus carinatum
Leukocytosis	Focal-onset seizure	Frontal bossing	Dyskinesia	Polydactyly
Leukopenia	Generalized-onset seizure	High palate	Dystonia	Recurrent fractures
Neutropenia	Global developmental delay	Hypertelorism	Frequent falls	Reduced bone mineral density
Pancytopenia	Hyperactivity	Long philtrum	Gait disturbance	Scoliosis
Thrombocytopenia	Intellectual disability	Low-set ears	Hyperreflexia	Skeletal dysplasia
Thrombocytosis	Lethargy	Macroglossia	Hyporeflexia	Spondylolysis
	Mental deterioration	Micrognathia	Involuntary movements	
	Migraine	Microphthalmia	Peripheral neuropathy	<b>SKIN/NAILS/HAIR</b>
<b>CARDIOVASCULAR</b>	Motor delay	Midface retrusion	Polyneuropathy	Abn. <sup>1</sup> hair morphology
Abn. <sup>1</sup> blood vessel morphology	Neurodegeneration	Ptosis	Positive Romberg sign	Abn. <sup>1</sup> of skin morphology
Abn. <sup>1</sup> heart valve morphology	Neurological speech impairment	Retrognathia	Spastic paraparesis	Angiokeratoma
Arrhythmia	Obsessive-compulsive behavior	Short neck	Spastic paraplegia	Anhidrosis
Atrial septal defect	Parkinsonism		Spasticity	Cafe-au-lait spot
Bradycardia	Seizure	<b>HEARING</b>	Tremor	Hirsutism
Cardiomyopathy	Sleep disturbance	Hearing impair. <sup>3</sup>		Hyperextensible skin
Congestive heart failure	Stereotypy	Sensorineural hearing impair. <sup>3</sup>	<b>MUSCLE/JOINT</b>	Hyperpigmentation of the skin
Dilated cardiomyopathy		Conductive hearing impair. <sup>3</sup>	Calf m. pseudohypertrophy	Hypertrichosis
Hypertension	<b>DIGESTIVE SYSTEM</b>		Flexion contracture	Hypohidrosis
Hypertrophic cardiomyopathy	Ascites	<b>KIDNEY</b>	Gowers's sign	Hypopigmentation of the skin
Left ventricular hypertrophy	Cholestasis	Chronic kidney disease	Hip dysplasia	Ichthyosis
Myocardial infarction	Cirrhosis	Focal segmental glomerulosclerosis	Hypertonia	
Patent ductus arteriosus	Constipation	Hydronephrosis	Hypotonia	<b>VARIOUS</b>
Patent foramen ovale	Diarrhea	Hyperechogenic kidneys	Joint hypermobility	Abn. <sup>1</sup> external genitalia
Pulmonary arterial	Gastroesophageal reflux	Nephrolithiasis	Joint laxity	Ambiguous genitalia
Tachycardia	Hepatic failure	Nephrotic syndrome	Lower limb muscle weakness	Cryptorchidism
Ventricular septal defect	Hepatic steatosis	Polycystic kidney dysplasia	Multiple joint contractures	Diabetes mellitus
	Hepatitis	Renal cyst	Muscle weakness	Hypospadias
<b>CNS MORPHOLOGY</b>	Hepatomegaly	Renal hypoplasia/aplasia	Muscular dystrophy	Hypothyroidism
Abn. <sup>1</sup> CNS myelination	Hernia of the abdominal wall	Renal insufficiency	Myopathy	Immunodeficiency
Abn. <sup>1</sup> of cerebral white matter	Jaundice	Renal tubular dysfunction	Myotonia	Paresthesia
Agnesis of corpus callosum	Nausea		Progressive muscle weakness	Recurrent fever
Brain atrophy	Pancreatitis	<b>METABOLISM</b>	Proximal muscle weakness	Recurrent infections
Cerebellar atrophy	Splenomegaly	Albuminuria	Rigidity	Sensory impairment
Cerebellar hypoplasia	Vomiting	Aminoaciduria	Skeletal muscle atrophy	
Cerebral ischemia		Elev. <sup>2</sup> hepatic transaminases	Talipes equinovarus	<b>VISION</b>
Encephalopathy	<b>GROWTH</b>	Elev. <sup>2</sup> serum creatine kinase		Abn. <sup>1</sup> of eye movement
Hypoplasia of corpus callosum	Decreased body weight	Elev. <sup>2</sup> serum creatinine	<b>RESPIRATORY</b>	Abn. <sup>1</sup> cornea morphology
Leukodystrophy	Failure to thrive	Elev. <sup>2</sup> alkaline phosphatase	Apnea	Cataract
Macrocephaly	Growth delay	Hyperammonemia	Asthma	Corneal opacity
Microcephaly	Intrauterine growth	Hyperbilirubinemia	Dyspnea	Glaucoma
Stroke	Obesity	Hypercholesterolemia	Pulmonary hemorrhage	Nystagmus
Ventriculomegaly	Overgrowth	Hyperglycemia	Pulmonary hypoplasia	Ophthalmoplegia
	Premature birth		Recurrent respiratory infections	Optic atrophy
	Short stature	Hypertriglyceridemia	Respiratory insufficiency	Reduced visual acuity
<b>CNS PHYSIOLOGY</b>	Tall stature	Hypocalcemia		Rod-cone dystrophy
Aggressive behavior	<b>HEAD AND FACE</b>	Hypoglycemia	<b>SKELETAL 1/2</b>	Strabismus
Attention deficit hyperactivity disorder	Abn. <sup>1</sup> facial shape	Hypokalemia	Abn. <sup>1</sup> vertebral morphology	Visual impairment
Autistic behavior	Abn. <sup>1</sup> of the dentition	Hyponatremia	Abn. <sup>1</sup> of limb bone morphology	Visual loss
Behavioral abnormality	Brachycephaly	Hypophosphatemia	Abn. <sup>1</sup> of the ribs	
Bilateral tonic-clonic seizure	Cleft lip	Lactic acidosis	Arachnodactyly	<sup>1</sup> Abn. = Abnormal/Abnormality
Cognitive impairment	Cleft palate	Metabolic acidosis	Brachydactyly	<sup>2</sup> Elev. = Elevated
Delayed speech/language	Coarse facial features	Proteinuria	Clinodactyly	<sup>3</sup> Impair. = Impairment
Dementia		Respiratory alkalosis	Dysostosis multiplex	

Important Notice: Submission of a completed and signed Consent Form is mandatory. Samples will not be processed or tested without an accompanying consent form. Please ensure the consent is attached to this request form.

Tel.: 17237350, 17237305

<https://www.agu.edu.bh/en/page/al-jawhara-center>

[molecular@agu.edu.bh](mailto:molecular@agu.edu.bh)



MOLECULAR GENETICS LABORATORY  
COMPREHENSIVE WHOLE EXOME SEQUENCING  
(WES)  
CONSENT FORM

**Patient information**

Name:	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female
Date of Birth: / /	CPR/ID No.
Contact Number:	E-mail:

**1. Purpose of the Test**

Whole Exome Sequencing (WES) is a genetic test that examines the exome – the portion of the genome that codes for proteins. Variants (changes) in these regions may cause or influence disease. This test may be done on you or your child (or unborn child, where applicable). WES can identify genetic changes related to your current symptoms. In some cases, it may also uncover findings unrelated to your symptoms but with medical significance.

In addition to analyzing individual gene changes, this test also includes backbone-supported copy number variation (bsCNV) analysis. bsCNV helps detect larger genetic changes, such as missing or extra pieces of DNA (deletions or duplications), including regions outside of genes that may not be captured by standard exome testing alone. This analysis improves the ability of the test to identify certain genetic conditions caused by large DNA changes.

It is important to understand that:

- A positive finding (pathogenic/likely pathogenic variant) does not always predict disease severity or guarantee a change in clinical management.
- A negative result does not rule out all possible genetic causes.
- Variants of uncertain significance (VUS) may be found, requiring further analysis or follow-up.

**2. Types of Test Results**

There are several possible types of genetic test results that may be reported:

- **Positive:**  
A positive or “abnormal” result means that a DNA variant has been detected, which is related to your or your child’s medical condition, or that indicates an increased risk of developing a certain disease in the future. It is possible to test positive for more than one variant. Positive results may include **pathogenic variants** (known to be associated with disease) and **likely pathogenic variants** (variants that are likely to be associated with disease).
- **Negative:**  
A negative or “normal” result means that no relevant variants were found that are associated with your or your child’s current medical condition or that would increase the risk of developing a disease in the future. This may suggest that no disease-related variants are present in the genes tested. However, genetic testing, while highly accurate, may not detect all existing variants. This can occur due to limitations in current scientific knowledge about certain genes or the technical boundaries of the testing method used.
- **Variant of Uncertain Significance (VUS):**  
Sometimes, testing identifies a DNA variant whose clinical impact is not yet fully understood. These are referred to as **variants of uncertain significance (VUS)**. If a VUS is identified in a gene that could be related to your or your child’s medical condition, additional testing or family studies may be recommended to help clarify its significance.

## 2. Types of Test Results (Continued)

- Secondary and Carriership Findings** Secondary and/or  
 Carriership Findings will be reported only if You have provided Your explicit consent by selecting “Yes.” During the course of genetic analysis, it is possible to identify a pathogenic variant that is not related to the primary reason for testing but is nonetheless clinically significant for Your health or that of Your family members. Such findings are considered medically relevant due to their clear and immediate implications. The following types of findings may be reported:
  - Secondary Findings:**  
 The American College of Medical Genetics and Genomics (ACMG) has issued guidelines for reporting certain findings, referred to as Secondary Findings, which are available at [www.acmg.net](http://www.acmg.net). These recommendations form the basis for Princess Al Jawhara Al Ibrahim Center for Molecular Medicine and Genetics (“Al Jawhara Center”) when reporting Secondary Findings.
  - Carriership Findings:**  
 Upon request, and if available, Al Jawhara Center will report Carriership Findings, which mainly include:
    - Variants indicating carrier status for recessive disorders. These findings
 will be reported only for variants that have undergone prior evaluation by Al Jawhara Center. Interpretation is based on medical and scientific information available at the time of analysis and may evolve as knowledge advances.

## 3. Limitations & Additional Considerations

- Not all disease-causing variants may be detected because of technical or knowledge limitations.
- Some variants may remain ambiguous (VUS) despite additional analyses.
- CNVs are reported at screening level and require orthogonal confirmation by MLPA or microarray.
- Samples from family members (parents, siblings) may help interpretation; your provider may request this.
- Whole Exome Sequencing (WES) may occasionally reveal unexpected familial relationships, such as non-paternity or other undisclosed biological connections.
- Interpretation of variants and carrier status is based on the medical and scientific information available at the time of analysis and may change as knowledge advances.
- Al Jawhara Center cannot guarantee detection of every medical condition associated with pathogenic or likely pathogenic variants. In some cases, the test may not yield valid results if the sample quality or quantity is insufficient, in which case an alternative sample may be requested.
- Samples and data may be stored (de-identified or coded) for quality control, development, or internal research purposes.
- You and/or your physician may be recontacted in the future if new information emerges about variants discovered.

**Disclaimer:** Please note that genetic analyses are not always conclusive. Due to technological limitations and/or the current state of medical knowledge, certain disease-causing variants may remain undetected. As a result, it is not possible to fully eliminate all risks associated with potential genetic conditions.

In some instances, the analysis may suggest the presence of a genetic abnormality when none exists (false positive) or fail to detect one when it is present (false negative). If the underlying cause of a false-positive or false-negative result cannot be identified by Al Jawhara Center, Al Jawhara Center shall not be held liable for any incomplete, potentially misleading, or inaccurate outcome of the analysis.

## 4. Reporting Preferences & Updates

You may choose whether or not to have certain categories of additional findings reported:

Option	Yes / No
Report the ACMG recommended Secondary Findings	<input type="checkbox"/> Yes <input type="checkbox"/> No
Report Carriership Findings	<input type="checkbox"/> Yes <input type="checkbox"/> No

If you do not make a selection, the default is **No** for both options.



#### 4. Reporting Preferences & Updates (Continued)

**Reanalysis/Updates:** As diseases, genes, and variants continue to be subjects of ongoing scientific research, it may be beneficial to re-evaluate Your Sample (“**Reanalysis**”) when new discoveries emerge. If relevant to Your health status, Al Jawhara Center may re-examine Your Sample for clinically significant variants, with only the raw DNA sequencing data being used for the Reanalysis. Should new (“novel”) findings differ from those in the original report, Al Jawhara Center will issue an updated report to You and/or Your Physician. You may also request a Reanalysis of Your Sample even without new clinical information; however, it is recommended to wait at least **one year** after the original Analysis or to request it when there are changes in the clinical presentation (phenotype).

#### 5. Confidentiality, Data Use, Data protection & Specimen Retention

- Your results and specimen will be treated confidentially and shared only with those you authorize, your physician, or as required by law.
- Unless otherwise authorized, no additional genetic tests will be performed beyond those you consent to.
- The biological specimen may be stored (in a coded or de-identified fashion) in accordance with institutional policy for quality, validation, or development purposes.
- Your personal and genomic data will be stored on secure institutional servers with restricted, role-based access and regular secure backups. Data are used solely for your clinical care and handled under applicable privacy policies.
- De-identified data may be submitted to public databases (e.g., ClinVar) to contribute to medical knowledge, with minimal information to help interpretation.

#### 6. Optional Research Consent for Future Use of Sample and Personal Data

I understand that my biological sample (“**Sample**”) and related personal data may help Al Jawhara Center to develop and improve diagnostic methods and potential treatments for genetic diseases in general. I acknowledge that neither I nor the person for whom I am the legal guardian or representative will receive any financial benefit or compensation from such use.

If I do **not** check a box, it will be considered as “**No**” for that item.

##### 6.1 Consent for Internal Research Yes No

I consent to the use of my Sample and personal data by Al Jawhara Center for scientific or medical research focused on understanding, early detection, and/or treatment of rare or inherited diseases. Because scientific knowledge advances over time, it is not possible to specify all future research purposes in detail. The Sample and data may therefore be used in medical research projects that cannot be foreseen today, provided such use complies with ethical and legal requirements.

##### 6.2 Consent for Long-Term Storage and Ownership Yes No

I consent to the secure storage of my Sample and related personal data for up to **10 years** after the final test report has been issued. I hereby donate and transfer ownership of the Sample to Al Jawhara Center, for continued use in authorized scientific or medical research aimed at improving prevention, detection, or treatment of rare and genetic diseases. After **10 years**, identifying information will be deleted, and the Sample will be kept only in a fully anonymized form, meaning that I can no longer be personally identified from it. Anonymized Samples may be used indefinitely for research purposes, provided they comply with ethical and legal standards.

*Signing this section is entirely optional and does not affect your clinical testing or diagnosis.*

## 7. Authorization & Consent

By signing below, I confirm that:

- I have read this consent document, or it has been explained to me in a language I understand.
- I have had the opportunity to ask questions, and my questions have been answered to my satisfaction.
- I understand the benefits, limitations, and risks of WES.
- I authorize the performance of WES as ordered by my physician.
- I understand I may withdraw consent **before testing begins**.
- I authorize the release of my results to my physician, authorized individuals, and myself (or my legal representative).

### Patient/Legal Representative

Patient Name:	Patient Signature:	Date: / /
If signed by a representative, relationship to patient:		
Ordering Physician:		
Physician Name:	Physician Signature:	Date: / /

## Specimen Requirements

Type of Analysis	Type of Specimen	Specimen Volume/Concentration		Transport Temperature
		Minimum	Ideal	
WES	Peripheral blood (EDTA tube)	5 ml	10 mL	+2°C to +8°C
WES	DNA	50ng/μl (10μl -100μl)	70 ng/μl (10μl -100μl)	-20°C to +8°C

### Note:

- Assure sample sterility.
- Close tubes properly.
- Label all samples.
- Send the sample on the day of collection if possible or store it at 4°C for up to **72 hours as maximum**. **“Older Samples May Be Rejected, if not stored properly”**.
- Close shipping box tightly and enclose requisition and consent form.